Back to search results
Not yet recruiting

Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

JPCX | {{ defaultRegistry.registryAnchorText }} NCT03988114 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) advanced breast cancer that have certain disease characteristics.

Time Commitment

Your participation in this trial could last up to 20 months, depending on your cancer type and how you and your tumor respond

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

• Participants must have completed (neo) adjuvant endocrine therapy and have cancer return after at least 12 months or have de novo cancer that has spread to other organs at diagnosis

• Participants must have 1 or more of the following: • A high grade tumor in tissue • Negative progesterone receptor (PR) status • Have cancer that has spread to the liver • Have a treatment-free interval (TFI) <36 months

• Participants must have HR+, HER2- breast cancer

• Participants must have adequate organ function

• Participants must not have cancer that has spread to other organs that has severely affected their function

• Participants must not have cancer that has spread to the brain that is unstable or untreated

• Participants must not have received endocrine therapy in the metastatic setting

• Participants must not have known active infection

• Participants must not have received prior endocrine therapy and had disease return within 12 months from completion of treatment

• Participants must not have received prior treatment with any cyclin-dependent kinase (CDK) 4 & 6 inhibitor or everolimus

Where to Participate

Where to Participate

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
{{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
{{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
{{site.siteStatus | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.